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Abstract
Introduction: Use of higher than standard doses of amikacin (AMK) has been proposed during sepsis, especially to
treat less susceptible bacterial strains. However, few data are available on drug concentrations during prolonged
therapy and on potential adverse events related to this strategy.
Methods: Sixty-three critically ill patients who required AMK administration for the treatment of severe infection
were included in this study. After a loading dose (LD, 18 to 30 mg/kg), the daily regimen was adapted using
therapeutic drug monitoring (TDM) of both peak (Cpeak) and trough (Cmin) concentrations. Target concentrations
had to give a ratio of at least 8 between Cpeak and the minimal inhibitory concentration (MIC) of the isolated
pathogen. A Cmin >5 mg/L was considered as potentially nephrotoxic. We recorded clinical and microbiological
responses, the development of acute kidney injury (AKI) during therapy and ICU mortality.
Results: The median AMK LD was 1500 (750 to 2400) mg, which resulted in a Cpeak/MIC ≥8 in 40 (63%) patients.
Increasing the dose in the 23 patients with a Cpeak/MIC <8 resulted in optimal Cpeak/MIC in 15 of these patients
(79%). In 23 patients (37%), Cmin was >5mg/L after the LD, notably in the presence of altered renal function at the
onset of therapy, needing prolongation of drug administration. Overall, only 11 patients (17%) required no dose or
interval adjustment during AMK therapy. Clinical cure (32/37 (86%) vs. 16/23 (70%), P = 0.18)) and microbiological
eradication (29/35 (83%) vs. 14/23 (61%), P = 0.07) were higher in patients with an initial optimal Cpeak/MIC than in
the other patients. The proportion of patients with clinical cure significantly improved as the Cpeak/MIC increased
(P = 0.006). Also, increased time to optimal Cpeak was associated with worse microbiological and clinical results. AKI
was identified in 15 patients (24%) during AMK therapy; 12 of these patients already had altered renal function
before drug administration. Survivors (n = 47) had similar initial Cpeak/MIC ratios but lower Cmin values compared to
nonsurvivors.
Conclusions: TDM resulted in adjustment of AMK therapy in most of our septic patients. Early achievement of an
optimal Cpeak/MIC ratio may have an impact on clinical and microbiological responses, but not on outcome. In
patients with impaired renal function prior to treatment, AMK therapy may be associated with a further decline in
renal function.
Introduction
Aminoglycosides are an important therapeutic option for
the treatment of life-threatening infections in critically ill
patients [1]. These drugs are usually used in combination
with b- lactams in infections cause by Gram-negative
bacteria to extend the spectrum of antimicrobial activity
[1,2], and remain one of the few available therapies
against multidrug-resistant pathogens, such as those pro-
ducing extended-spectrum b-lactamases [3]. Recent
guidelines on the treatment of sepsis have recommended
using combination therapy, especially in patients with
septic shock or if Pseudomonas aeruginosa is suspected
[4,5]. In a meta-analysis, Kumar et al. also suggested that
combination therapy including aminoglycosides
increased survival rates among patients suffering from
septic shock of various etiologies and with an expected
mortality exceeding 25% [6].
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The antibacterial activity of aminoglycosides is related
to the peak concentration (Cpeak) obtained after drug
injection [7]. In particular, a ratio between Cpeak and the
minimal inhibitory concentration (MIC) of the pathogen
of greater than eight has been associated with increased
clinical cure in uncomplicated infections [8]. Neverthe-
less, sepsis may significantly alter the pharmacokinetic
(PK) properties of these drugs, with increased distribution
volume (Vd) and altered clearance, resulting in insuffi-
cient drug concentrations for the empiric treatment of
P. aeruginosa [9,10]. In this respect, a higher than recom-
mended loading dose (LD) of amikacin (AMK) was
necessary to rapidly achieve therapeutic drug concentra-
tions in patients with severe sepsis and septic shock [11].
However, the clinical impact of this strategy has not yet
been studied among critically ill patients. Moreover, as
these patients often suffer from acute kidney injury
(AKI), which contributes to drug accumulation, the use
of higher than recommended dose regimens may result
in elevated trough concentrations (Cmin), which are asso-
ciated with an increased risk of toxicity [12].
Galvez et al. showed that a daily dose of at least
30 mg/kg of AMK was necessary to achieve optimal
drug concentrations [13]; no increase in renal toxicity
was reported compared to lower dose regimens, includ-
ing 15 and 25 mg/kg. However, overall mortality in this
study [13] was only 9% and one may argue that these
patients did not really represent a critically ill population
with different organ dysfunctions and poor outcomes.
Moreover, in such patients, the use of large amounts of
fluid, of vasopressors and/or of renal replacement ther-
apy may significantly impact on PK drug changes over
time, which would be unpredictable if therapeutic drug
monitoring (TDM) is not routinely performed [14].
The aim of this study was, therefore, to evaluate the
impact of an AMK regimen based on dose adjustment
using daily TDM in an ICU population with severe sep-
sis and septic shock.
Materials and methods
Patients
The study was conducted in the 20-bed ICU of the Uni-
versity Hospital in Wrocław, Poland, between May 2009
and May 2012. The University Bioethics Committee
approved the study protocol; written consent was waived
because TDM of aminoglycosides is routine practice in
our ICU. All consecutive adult (>18 years) patients with
a diagnosis of severe sepsis or septic shock according to
standard criteria [15] were included if: a) the initial anti-
biotic therapy, other than amikacin, was appropriate
(that is, the pathogen was sensitive in vitro to the first-
line therapy); b) the attending physician decided to initi-
ate AMK therapy. Drug regimens for other antibiotics
were adapted to renal function according to standard
recommendations. Exclusion criteria were: neutropenia
(<1000/mm3), burns, myasthenia gravis, pregnancy, body
mass index (BMI) >40 kg/m2, chronic renal failure
requiring dialysis (HD) or the use of continuous renal
replacement therapy (CRRT) at the onset of therapy.
Infection diagnosis
The site of infection was diagnosed according to the CDC/
NHSN criteria [16]. The protected non-bronchoscopic
method (mini-bronchoalveolar lavage (BAL)) was used for
microbiological diagnosis of ventilator-associated pneumo-
nia (VAP), with a cutoff of at least 104 cultures/mL [17].
All biological samples were analyzed qualitatively and
quantitatively according to established microbiological
diagnostic criteria [16]. For each isolate, drug susceptibility
tests (Etest, bioMérieux, Marcy l’Etoile, France) were per-
formed to identify the MIC.
Amikacin regimen and drug measurement
Amikacin therapy was combined with a first-line antibio-
tic, such as a b-lactam, sulphonamide or quinolone,
when the Etest confirmed the presence of susceptible
pathogen with an MIC ≤16 mg/L for the drug. Amikacin
could be administered either: a) at the same time as the
first-line therapy in case of previously colonization and
an already known MIC; or b) on the second day of first-
line therapy, when the MIC was available through the
Etest from positive microbiological samples. The initial
AMK (Biodacin; Bioton, Warsaw, Poland) dose was cal-
culated using the ideal body weight (IBW), according to
the Devine formula [17], for patients with a BMI between
18 and 28. In patients with a BMI <18, the total body
weight (TBW) was used to calculate the AMK regimen. If
the BMI was greater than 28 kg/m2, the dose was calcu-
lated using the adjusted body weight (ABW), which was
calculated as: ABW = IBW + 0.4 (TBW-IBW) [18].
Immediately after the end of the LD (30 minutes,
diluted in 100 mL of 0.9% NaCl), a 4-ml blood sample
was taken to assess drug concentrations (Cmax). For
each of the subsequent doses needing TDM, blood was
sampled 30 minutes after the end of the dose for Cpeak
and just before the next administration for Cmin. Blood
samples were immediately sent to the laboratory for
drug concentration measurement, using a validated qua-
litative and quantitative enzyme multiplied immunoassay
technique (EMIT) on the Viva-E™ analyzer (Siemens,
Dublin, Ireland). These measurements were controlled
daily using internal and external control systems. The
limit of quantification (LOQ) was 0.8 mg/L. Drug con-
centrations were measured daily only if dose correction
or prolongation was necessary or if there were changes in
serum creatinine (sCr), otherwise TDM was performed
every 2 days. Because drug elimination is almost entirely
dependent on renal function, we a priori defined two
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subgroups of patients, according to the baseline creati-
nine clearance (CrCl, that is <50 mL/min or ≥50 mL/
min) estimated by the Cockroft-Gault formula [19], for
separate analyses.
Amikacin dose adjustment and PK analysis
The LD was established from the Etest estimation of MIC;
if the MIC was ≤4 mg/L, the LD was 18 to 24 mg/kg (D1),
but for MICs of 4 to 16 mg/L the LD was 25 to 30 mg/kg
(D2). After the LD, AMK was administered once a day for
a maximum of 5 to 7 days. The target Cpeak/MIC was
between 8 and 12, with Cmin ≤5 mg/L. Potential toxicity of
AMK was considered at a Cmin >5 mg/L. If the Cpeak/MIC
was <8, the daily dose (DD) was increased by 25 to 30%
to a maximum of 30 mg/kg. If the Cpeak/MIC was >12,
the DD was reduced by 25 to 30% to a minimum of
7.5 mg/kg. If Cmin was >5 mg/L, the time between two
administrations was prolonged to 12 hours (to a maxi-
mum of 72 hours) to allow another drug concentration
measurement; following dose was given only when Cmin
was ≤5 mg/L. The probability of attainment (PTA) of opti-
mal Cpeak/MIC was calculated using the initial Cpeak for a
wide range of MICs (0.5 to 16 mg/L). PK parameters were
calculated using a one-compartment model (Kinetica 5.0;
Thermo Fisher Scientific, Poch SA, Gliwice, Poland). The
following parameters were obtained: total volume of distri-
bution (Vd), half-life time (t1/2), the area under the curve
(AUC) and drug clearance (CL).
Clinical and microbiological end points
The main end points of this study were clinical efficacy,
microbiological response and the development of AKI.
Clinical efficacy assessment was conducted on day 7
after the initiation of AMK therapy and was based on
clinical signs (body temperature, BT), laboratory para-
meters (white blood cell count, procalcitonin and
C-reactive protein) and the regression of tissue-related
radiological signs or microbiological samples. Clinical
cure was defined as complete resolution of clinical signs
(BT <37.5°C) and laboratory (reduction of procalcitonin
or C-reactive protein of more than 80% compared to
baseline)/microbiological abnormalities (absence of
pathogens on different samples), with no further need
for antibiotic therapy or source control. Clinical failure
was defined as a persistence or progression of clinical
symptoms of infection, initial recovery followed by dete-
rioration, change in wider spectrum antibiotic therapy
(escalation), increased radiological infiltrates and/or
worsening of laboratory data. Eradication was defined as
a negative culture on day 7 of therapy. Microbiological
failure was defined as the persistence of pathogen(s)
in laboratory samples or as the development of a new
infection. AKI was defined according to the AKIN criteria,
that is, an increase in sCr of ≥0.3 mg/dL and/or a
decreased urine output (<0.5 ml/kg/h for more than
6 hours) during AMK therapy until 72 hours after drug
discontinuation [20]. Need for renal replacement therapy
(RRT) was also considered as AKI.
Statistical analysis
Statistical analyses were performed using the SPSS 13.0
for Windows NT software package (SPSS Inc., Chicago,
IL, USA). Descriptive statistics were computed for all
study variables. Discrete variables were expressed as
counts (percentage) and continuous variables as means ±
standard deviation (SD) or median (25th to 75th percen-
tiles). Differences between groups were assessed using a
chi-square, Fisher’s exact test, Student’s t test, or Mann-
Whitney U test, as appropriate. A P <0.05 was considered
to be statistically significant.
Results
Sixty-three patients were included in this study. The
patients’ characteristics are shown in Table 1. Amikacin
was combined with carbapenems (n = 21), cephalospor-
ins (n = 14), piperacillin/tazobactam (n = 11), colistin
(n = 8), trimethoprim/sulfamethoxazole (n = 3), ampicil-
lin/sulbactam (n = 2), or other drugs (n = 4). The most
common site of infection was the lung (n = 32) and 23
patients (44%) had positive blood cultures. The isolated
Gram-negative bacteria were: P. aeruginosa (n = 19),
Escherichia coli (n = 9), Acinetobacter baumanii (n = 7),
Klebsiella pneumoniae (n = 6), Enterobacter cloacae
(n = 4), Proteus mirabilis (n = 3) and others (n = 13). In
41 patients, AMK was initiated together with the first-
line therapy; in the 22 other patients, AMK was started
on the second day of therapy. The median MIC for ami-
kacin was 4 (1 to 16) mg/L. Septic shock occurred in 20
patients (32%), with an overall ICU mortality of 25%.
Median PK parameters for the LD were: volume of
distribution 0.42 L/kg, total clearance 3.3 mL/min and
half-life 5.4 hrs (Table 2). Median duration of therapy
was 5 [3-6] days. The average AMK LD was 1500 (750
to 2400) mg; this resulted in a median Cpeak of 42.6
(20.3 to 142.0) mg/L and a Cpeak/MIC ≥8 in 40 (63%)
patients. Patients with initial optimal Cpeak/MIC had
similar characteristics than others, with the exception of
lower C-reactive protein and procalcitonin on the first
day of therapy (Table 1). A similar proportion of
patients receiving D1 had an optimal Cpeak/MIC (26/39
(67%)) compared to those receiving D2 (14/24 (58%),
P = 0.59). Among these 40 patients, 24 had Cpeak/MIC
>12, requiring daily dose reduction (median 1200 (600
to 1800) mg). Only 13 patients (21%) had a Cpeak value
greater than 64 mg/L, which corresponds to the target
concentration to treat susceptible strains of P. aerugi-
nosa. Notably, 5/39 (13%) patients receiving D1 and 8/
24 (33%) receiving D2 achieved this target (P = 0.06).
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Table 1 Demographics and clinical data of patients on drug initiation (n = 63) and with regard to initial Cpeak/MIC











Female/Male, n 22 / 41 14 / 30 8 / 11 13 / 26 9 / 16
Age (years) 59 ± 16 58 ± 15 60 ± 18 59 ± 15 59 ± 18
IBW (kg) 65 ± 10 65 ± 9 64 ± 10 64 ± 10 66 ± 9
ABW (kg) 67 ± 12 68 ± 13 66 ± 12 67 ± 13 67 ± 10
APACHE II score 21 (19-25) 21 (19-24) 23 (18-27) 21 (15-31) 21 (12-27)
SOFA 10 (8-11) 10 (8-11) 9 (8-11) 10 (7-11) 9 (8-11)
Severe sepsis/septic shock, n 43 / 20 26 / 14 17 / 6 28 / 11 15 / 9
Mechanical ventilation, n (%) 63 (100) 40 (100) 23 (100) 39 (100) 24 (100)
Immunosuppression, n (%) 13 (21) 8 (20) 5 (22) 8 (21) 5 (21)
Concomitant nephrotoxic agents, n (%)
Vancomycin 4 (6) 3 1 3 1
Colistin 8 (13) 5 3 5 3
Amphotericin B - - - - -
NSAIDs 24 (38) 15 9 14 10
Contrast medium 11 (17) 8 3 7 4
Diuretics 15 (24) 10 5 9 6
Others 1 (2) 1 - 1 -
Type of infection, n (%)
CR-BS 10 (16) 6 4 5 5
VAP 34 (54) 24 10 23 11
HAP 7 (11) 6 1 6 1
Peritonitis 6 (9) 3 3 3 3
Others 6 (9) 1 5 2 4
Temperature, °C 37.7 ± 1.0 37.9 ± 0.8 37.6 ± 1.1 37.7 ± 1.0 38.0 ± 0.7
White blood cells, n × 103/mm3 12.7 (8.5-16.7) 12.6 (8.4-19.3) 12.8 (8.8-15.9) 13.6 (8.8-17.1) 12.1 (8.1-20.1)
C-reactive protein, ng/mL 121 (69-166) 108 (60-159) 139 (102-196)* 113 (76-159) 132 (98-194)#
Procalcitonin, ng/mL 1.2 (0.5-5.9) 0.7 (0.3-4.6) 1.8 (1.1-6.8)* 0.7 (0.3-5.5) 2.0 (1.2-7.9)#
Hematocrit, % 27.9 (25.7-30) 28.8 (25.8-31.6) 27.0 (25.5-29.2) 28.0 (22.8-39) 26.7 (22.3-38.1)
Serum proteins, g/dL 4.9 ± 0.7 4.5 ± 0.6 5.0 ± 1.0 5.0 ± 0.8 4.9 ± 0.8
Albumin, g/dL 2.2 ± 0.5 2.1 ± 0.4 2.3 ± 0.5 2.3 ± 0.6 2.1 ± 0.3
Serum creatinine, mg/dL 1.1 ± 0.8 1.1 ± 0.8 1.1 ± 0.7 1.1 ± 0.9 1.0 ± 0.7
Creatinine clearance, mL/min 67 (50-118) 81 (52-108) 65 (45-130) 80 (40-108) 64 (50-143)
ICU stay, days 50 (18-65) 37 (14-77) 46 (11-58) 48 (24-68) 47 (17-66)
ICU mortality, n (%) 16 (25) 11 (27) 5 (22) 8 (21) 8 (33)
Data are presented as counts (percentage), mean (± standard deviation (SD)) or median (interquartile range (IQR). *P <0.05 vs. Cpeak/MIC ≥8;
#P<0.05 vs. D1. Cpeak,
peak concentration; MIC, minimum inhibitory concentration; D1, loading dose 18 to 24 mg/kg; D2, loading dose 25 to 30 mg/kg; IBW, ideal body weight; ABW,
adjusted body weight; APACHE, acute physiology and health evaluation; SOFA, sequential organ failure assessment; CR-BSI, catheter-related bloodstream
infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia.
Table 2 Pharmacokinetic parameters of amikacin loading dose according to the creatinine clearance (CrCl) at the
onset of therapy
Parameter All patients (n = 63) CrCl ≥50 mL/min (n = 46) CrCl <50 mL/min (n = 17)
Vd (L) 26.32 (8.4-51.7) 25.7 (8.5-49.3) 38.8 (8.4-46.7)
Vd (L/kg) 0.42 (0.12-1.03) 0.40 (0.12-1.03) 0.66 (0.2-0.8)*
t1/2 (h) 5.4 (0.8-19.9) 4.9 (0.8-11.0) 7.8 (3.2-19.1)*
CL (mL/min) 3.3 (0.6-25.3) 3.4 (1.5-25.8) 3.3 (0.6-9.9)
AUC0-24 (mg*h/L) 462 (58-1867) 361 (58-1045) 507 (153-1867)
Data are presented as median (ranges). *P = 0.05 vs. CrCl ≥50 mL/min. Vd, volume of distribution; t1/2 , half-life; CL, drug clearance; AUC0-24, area under the curve
for the first day of therapy.
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The PTA of optimal Cpeak/MIC was ≥90% for MIC
≤3 mg/L, regardless of the dose initially given (Figure 1).
The daily dose was increased in the 23 patients (37%) with
Cpeak/MIC <8 (median dose 2000 (1000 to 2400) mg),
resulting in optimal Cpeak/MIC in 15 (79%) (Table 3).
In 23 patients (37%), Cmin was >5 mg/L after the LD,
and the drug interval was increased (Table 3). Patients
with CrCl ≥50 ml/min less frequently needed interval
adjustment (8/43 (19%)) than those with CrCl <50 ml/min
(15/20 (75%), P <0.001). There were no differences in the
proportion of patients with Cmin >5mg/L between those
receiving D1 and D2 (14/39 (36%) vs. 9/24 (38%), P =
0.93). On day 2 of therapy, 10 patients (15%) still had a
Cmin >5mg/L, which returned below this threshold on
day 3. Overall, only 11 patients (17%) required no dose or
interval adjustment during AMK therapy.
Clinical cure was obtained in 51/60 (85%) patients and
microbiological eradication in 43/58 (72%) patients; 3
patients could not be evaluated because they died before
the end of therapy and 2 patients were weaned from
mechanical ventilation and had no further microbiologi-
cal samples taken to assess microbiological response.
Specifically, clinical cure and microbiological eradication
were achieved in 32/37 (86%) and 29/35 (83%) patients,
respectively, with initial optimal Cpeak/MIC, compared
to 16/23 (70%) and 14/23 (61%), respectively, patients
with insufficient initial Cpeak/MIC (P = 0.18 and P =
0.07). The proportion of patients with clinical cure
improved as the initial Cpeak/MIC increased (Figure 2).
Moreover, patients with initial optimal Cpeak had signifi-
cantly higher microbiological eradication and clinical
cure rates than those achieving Cpeak/MIC ≥8 after
more than 3 days of therapy (Figure 3).
There was no particular difference among patients
receiving AMK as the first-line therapy compared to
others for microbiological eradication (31/40 vs. 12/18,
P = 0.51), clinical cure (35/41 vs. 15/19, P = 0.71) and
mortality (10/41 vs. 6/22, P = 1.00). Similarly, patients
with infections due to P. aeruginosa or A. baumanii
(n = 26), had similar eradication (15/23 vs. 28/35, P =
0.23) and clinical cure rates (22/26 vs. 29/34, P =1.00)
than others, but lower Cpeak/MIC (7.5 (5 to 11.5) vs. 13
(8 to 23.5), P = 0.005) and a trend toward fewer optimal
Cpeak/MIC (13/26 vs. 27/37, P = 0.07). Nevertheless, this
Figure 1 Probability of attaining (PTA) the target Cpeak/MIC of ≥8 for various MICs when 18 to 24 mg/kg or 25 to 30 mg/kg dose
regimens were administered.
Table 3 Summary of dose adjustments during the study
period
Dose administration
24 hrs 36 hrs 48 hrs 72 hrs
Dose management Increased 14 2 4 3 23
Unchanged 11 3 2 - 16
Decreased 15 2 4 3 24
40 7 10 6 63
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did not affect ICU mortality (5/26 vs. 11/37, P = 0.39,
respectively). No particular differences were found when
patients with respiratory infections (n = 41) were com-
pared to others or when patients concomitantly treated
with carbapenems (n = 21) were compared to those
receiving other additional drugs (data not shown).
AKI developed in 15 patients (24%) during AMK ther-
apy; among these, 12 patients had CrCl <50 ml/min at
the onset of therapy and 6 of them eventually under-
went RRT. The median time to develop AKI after the
administration of the LD was 3 [2-6] days. Patients with
AKI had similar Cpeak values to patients without AKI
(46.8 (39.1 to 56.2) vs. 40.7 (33.8 to 53.9) mg/L, P =
0.44), but the same proportion of optimal initial Cpeak/
MIC ratios (12/15 (80%) vs. 28/46 (61%), P = 0.27). Cmin
values were higher (10.8 (5.1 to 15.5) vs. 1.8 (0.6 to 4.7)
mg/L, P <0.001), initial CrCl was lower (44 (25 to 51)
vs. 92 (65 to 132) mL/min, P <0.001) while total AMK
dose was similar (3.9 (1.5 to 7.5) vs. 5.0 (2.5 to 15) g,
P = 0.25) in patients with AKI than in those without.
Survivors (n = 47) had similar initial Cpeak/MIC ratios (8
(6 to 18) vs. 13 (6 to 23), P = 0.26) than nonsurvivors,
but lower Cmin values (1.8 (0.6 to 5.3) vs. 7.6 (3.6 to
13.5) mg/L, P = 0.002).
Discussion
We have shown that higher than standard drug doses
are initially necessary to obtain adequate Cpeak/MIC in
critically ill septic patients. Moreover, TDM appears
mandatory during aminoglycoside therapy, because only
17% of patients required no drug dose adjustment. Clin-
ical cure and microbiological eradication occurred more
frequently, although not statistically different, in patients
with an optimal initial Cpeak/MIC than in other patients;
however, there were no differences in ICU outcome
between groups.
Because of widespread bacterial resistance to several
groups of antimicrobials, AMK remains one of the more
frequently prescribed aminoglycosides in critically ill
patients, despite a very narrow therapeutic index and
Figure 2 Proportion of patients achieving microbiological eradication or clinical cure, according to different ratios of initial Cpeak/MIC.
Number of patients: Cpeak/MIC ≤4 (n = 7); Cpeak/MIC 5 to 6 (n =12); Cpeak/MIC 7 to 8 (n = 12); Cpeak/MIC 9 to 12 (n = 8); Cpeak/MIC >12 (n = 24).
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potential adverse events. Administration of a once daily
dose of aminoglycosides in the treatment of severe
infection has been widely accepted, because it achieves a
higher Cpeak than multiple daily doses and is associated
with a lower risk of AKI [7,12,21]. However, PK changes
occurring during sepsis require the use of a higher
AMK dose (25 to 30 mg/kg) to rapidly achieve optimal
Cpeak/MIC, especially when treating less susceptible
strains [11,13]. In burn patients, even higher dose regi-
mens (38 mg/kg) have been proposed to optimize drug
therapy [22]. In our study, 63% of patients achieved this
PD target after the LD. These data are similar to those
reported in recent studies on large ICU cohorts [11,13].
Nevertheless, important differences need to be under-
lined. First, we adapted the drug LD to the MIC of the
pathogen, obtained before the onset of therapy. This
approach was chosen to avoid the unnecessary risk of
high AMK doses as we used this drug only for targeted
therapy. When used as empirical therapy, drug regimens
should be adapted rapidly to treat less susceptible
strains, such as P. aeruginosa or A. baumanii, requiring
a daily dose of at least 25 mg/kg and a Cpeak target
above 64 mg/L. Second, even patients with an MIC of 8
to 16 mg/L received AMK, although according to
Figure 3 Proportion of patients achieving microbiological eradication or clinical cure, according to the time (days) needed to achieve
and Cpeak/MIC ≥8. *P = 0.05 (eradication) and P = 0.01 (clinical cure).
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EUCAST recommendations [23], these pathogens are
resistant to the drug and optimal Cpeak can hardly be
obtained in these situations. Although some authors
have reported combining a very high AMK regimen
(50 mg/kg) with high-flow CRRT to obtain adequate
Cpeak/MIC and rapidly reduce drug concentrations
below the threshold of potential toxicity [24], this
approach needs to be further validated and the choice of
another antimicrobial should be considered for strains
with MICs 8 to 16 mg/L. Finally, we calculated drug
regimens according to IBW/ABW and adjusted dose for
underweight (BMI <18) or obese (BMI >28) patients
[18,25]. Taccone et al. used a 25 mg/kg LD of AMK calcu-
lated using TBW; but the authors noted that there would
have been a significant decrease in the proportion of
patients with optimal Cpeak if this regimen had been used
based on IBW [11]. Similarly, Galvez et al. reported that an
AMK LD of 30 mg/kg resulted in a larger number of
patients with optimal Cpeak than an LD of 25 mg/kg, if
IBW was used to calculate drug dose regimens [13]. In our
cohort, only 33% of patients receiving at least 25 mg/kg
achieved optimal Cpeak values to treat less susceptible
strains. These data suggest a relative underestimation of
AMK doses in ICU patients when IBW is applied and the
need for even higher doses (30 to 35 mg/kg) to improve
drug efficacy. Importantly, the risk of excessive drug dosing
in obese patients and the exact role of IBW- or ABW-
guided dose prescription needs to be further studied.
Aminoglycosides have been used for decades. However,
monotherapy is effective only in urinary tract infections,
and meta-analyses have failed to show the superiority of
aminoglycoside-b-lactam combination therapy compared
to b-lactams alone [1]. However, aminoglycosides were
usually given as multiple daily injections and no peak
monitoring was performed to optimize the drug regimen.
Currently, b-lactams remain the first-line therapy in
severe sepsis and septic shock [4]; furthermore, combina-
tion with an aminoglycoside may improve patient out-
comes, especially in the most severe cases [6]. To the
best of our knowledge, this study is the first to report on
the clinical and microbiological effects of using high
doses of aminoglycosides to reach therapeutic Cpeak in
critically ill septic patients. Recently, Delannoy et al.
found that short-term combination therapy with an ami-
noglycoside for ICU-acquired bacteremias increased sur-
vival and reduced the duration of mechanical ventilation
[26]. Our data suggest that early optimizing aminoglyco-
side peaks according to the MICs of the isolated patho-
gens may result in further increased therapeutic efficacy
and in the clinical cure of severe infections.
If using higher than standard AMK doses is mandatory
to optimize its antibacterial activity, the main concern is
related to the potential development of renal damage.
Aminoglycosides are eliminated by the kidneys and drug
uptake by tubular cells is a saturable mechanism when
drug concentrations exceed 15 μg/mL [27]. In our study,
24% of patients developed AKI, independent of the initial
LD they received. Similarly, Gerlach et al. found AKI in
12% of critically ill surgical patients treated with AMK,
especially if combined with other nephrotoxins [28]. In
contrast, Galvez et al. found no increased risk of AKI
between a drug regimen using 30 mg/kg compared to
others using lower doses [13]. Clinical studies have sug-
gested that AKI is more prevalent when there is pre-
existing renal impairment or diabetes mellitus or in the
case of prolonged therapy [27]. Our data also suggest
that the risk of drug accumulation is dependent on base-
line renal function, with higher Cmin values in patients
with CrCl <50 mL/min. Indeed, 12/15 patients who
developed AKI during AMK therapy already had reduced
CrCl at the onset of therapy, making it difficult to sepa-
rate the toxic effects of the drug from the kidney damage
induced by sepsis. In patients without critical illness,
the use of high aminoglycoside dose regimens did not
result in AKI, provided that Cmin was monitored [29,30].
Nevertheless, ICU patients have several risk factors for
AKI, including hypovolemia, shock, use of diuretics or
contrast medium and the presence of chronic kidney dis-
ease prior to ICU admission [31], and aminoglycosides
could further aggravate the development of renal dys-
function in this population. Among 360 consecutive
patients treated with aminoglycoside therapy in an ICU,
AKI occurred in 58% and was independently associated
with a lower glomerular filtration rate, hypotension, a
higher prevalence of diabetes and a more frequent asso-
ciation with other nephrotoxic drugs [32]. Simulation of
the clinical effects of amikacin given once daily also
showed that, for an MIC of 16 μg/mL and a desired cure
rate of at least 90%, the probability of renal failure was
expected to be 100% [33]. Thus, an increase in sCr
should be expected among ICU patients with pre-existing
renal dysfunction, high disease severity, and infections
with pathogens with high MICs when high-dose amino-
glycosides adapted to the optimal Cpeak/MIC are used.
Our study has some limitations. First, we did not eval-
uate the effectiveness of high vs. standard AMK doses.
Although it is possible that this strategy would provide
some benefits when compared to standard regimens,
because of an increased postantibiotic effect and a
potentially reduced risk of drug resistance development,
we cannot draw any conclusions regarding the superior-
ity of optimized peak concentrations in this setting.
Second, we used the Cockroft-Gault formula to estimate
renal function, although this approach has several lim-
itations when applied to critically ill patients. Third, we
could not demonstrate any survival benefits for those
patients who rapidly achieved optimal Cpeak. This may
be because of the higher proportion of optimal initial
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Cpeak/MIC ratios among patients who subsequently
developed AKI, which may have blunted any potential
beneficial effect of optimized therapy.
Moreover, even empirical aminoglycoside therapy with
optimized Cpeak has never been demonstrated to improve
outcome among critically ill patients. Further studies are
needed to address this point in large ICU cohorts.
Fourth, in one-third of the patients, AMK was initiated
only when MIC was obtained by Etest. Thus, this could
be considered as being in contrast to common recom-
mendations, which suggest early administration of appro-
priate antibiotic therapy to improve survival rates in
septic patients [6]. Nevertheless, the benefits of this
approach have not been clearly demonstrated for combi-
nation therapy and this strategy would have resulted in
patients with pathogens resistant to the drug being
exposed to potentially undesirable adverse events of the
drug without likely benefit. In addition, for patients with-
out positive microbiological samples, no microbiological
assessment would have been possible. Fifth, we could not
provide any data on the appropriateness of the first-line
therapy (that is b-lactams) concentrations, which could
have been an additional determinant in the evaluation of
microbiological eradication and clinical cure. Sixth, the
ranges of delivered dose of AMK were quite large in each
group. Thus, it is possible that more precise regimens
(that is 20 mg/kg vs. 30 mg/kg) would have resulted in
different results. Also, the quite limited number of
patients included over a 3-year period was related to the
strict inclusion and exclusion criteria; this may have
introduced a selection bias in this study. Finally, we did
not specifically calculate a sample size to estimate the
number of patients to be included in this study, as we
could not identify any previous data describing the effects
of initial optimal Cpeak values on clinical and microbiolo-
gical response in critically ill patients.
Conclusions
TDM resulted in adjustment of AMK therapy in most of
our septic patients. Early achievement of an optimal
Cpeak/MIC ratio may have an impact on clinical and
microbiological responses, but not on outcome. In
patients with impaired renal function prior to treatment,
AMK therapy may be associated with a further decline
in renal function.
Key messages
- Therapeutic drug monitoring was necessary to
adjust amikacin dose in most septic patients.
- Early achievement of optimal Cpeak/MIC may have
an impact on clinical and microbiological responses,
but not on outcome.
- Pre-existing altered renal function is associated




ABW: adjusted body weight; AKI: acute kidney injury; AKIN: acute kidney
injury network; AMK: amikacin; APACHE: acute physiology and health
evaluation; AUC: area under the curve; BAL: bronchoalveolar lavage; BMI:
body mass index; BT: body temperature; CDC: Centers for Disease Control;
CL: drug clearance; Cmax: maximum concentration; Cmin: minimum
concentration; Cpeak: peak concentration; CrCl: creatinine clearance; CRRT:
continuous renal replacement therapy; D1: loading dose 18 to 24 mg/kg;
D2: loading dose 25 to 30 mg/kg; DD: daily dose; EMIT: enzyme multiplied
immunoassay technique; EUCAST: European Committee on Antimicrobial
Susceptibility Testing; IBW: ideal body weight; LD: loading dose; LOC: limit of
quantification; MIC: minimum inhibitory concentration; NHSN: National
Healthcare Safety Network; PD: pharmacodynamics; PK: pharmacokinetics;
PTA: probability of target attainment; RRT: renal replacement therapy; sCr:
serum creatinine; SD: standard deviation; SOFA: sequential organ failure
assessment; t1/2: half-life; TBW: total body weight; TDM: therapeutic drug
monitoring; VAP: ventilator-associated pneumonia; Vd: distribution volume.
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